Cited by 179Thyroid Disorders and TreatmentsAngiogenesis and VEGF in CancerThyroid Cancer Diagnosis and Treatment

Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo.

Open access
Sato, K, Yamazaki, K, Shizume, K, Kanaji, Y, Obara, T, Ohsumi, K, Demura, H, Yamaguchi, S +1 more·1995·Journal of Clinical Investigation

Abstract

To elucidate the pathogenesis of thyroid gland hypervascularity in patients with Graves' disease, we studied the expression of mRNAs for vascular endothelial growth factor (VEGF) and its receptor, Flt family, using human thyroid follicles in vitro and thiouracil-fed rats in vivo. Human thyroid follicles, cultured in the absence of endothelial cells, secreted de novo-synthesized thyroid hormone in response to thyroid-stimulating hormone (TSH) and Graves' IgG. The thyroid follicles produced VEGF mRNA but not flt-1 mRNA. The expression of VEGF mRNA was enhanced by insulin, tumor-promoting phorbol ester, calcium ionophore, dibutyryl cAMP, TSH, and Graves' IgG. When rats were fed thiouracil for 4 wk, their serum levels of TSH were increased at day 3. VEGF mRNA was also increased on day 3, accompanied by an increase in flt family (flt-1 and KDR/ flk-1) mRNA expression. These in vitro and in vivo findings suggest that VEGF is produced by thyroid follicles in response to stimulators of TSH receptors, via the protein kinase A and C pathways. VEGF, a secretable angiogenesis factor, subsequently stimulates Flt receptors on endothelial cells in a paracrine manner, leading to their proliferation and producing hypervascularity of the thyroid gland, as seen in patients with Graves' disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci118164

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The activity of Ang-1 can enhance VEGF receptor function for vascular development, remodeling, stabilization, and final maturation.

    “The activity of Ang-1 can enhance VEGF receptor function for vascular development, remodeling, stabilization, and final maturation (85)(86)(87)”

    From Adipose tissue remodeling and obesity (2011) · cites this paper as [87]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Ingbar, S. H., and K. A. Woeber. The Thyroid. 1981. In Williams Textbook of Endocrinology. 6th ed. J. D. Wilson and D. W. Foster, editors. W. B. Saunders Co., Philadelphia. 117-247.
  2. Shibuya, M. 1995. A review on the role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res. 67:in press.

Cited by

Sorted by citations

Authors
Sato, K., Yamazaki, K., Shizume, K., Kanaji, Y., Obara, T., Ohsumi, K., Demura, H., Yamaguchi, S., & Shibuya, M.
Affiliations
  • Tokyo Women's Medical University (JP)
  • Institute of Medical Science, The University of Tokyo (JP)
Venue
Journal of Clinical Investigation
Published
1995-09-01
Volume
96
Issue
3
Pages
1295-1302
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2163384356
Cited by
179
References
42
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 1 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 7 · 2014: 2 · 2013: 7 · 2012: 2
FWCI
4.75
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Institute of Medical Science, University of Tokyo
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
Graves' disease, vascular endothelial growth factor, VEGF mRNA expression, Flt-1, KDR/Flk-1, thyroid follicles, thyroid-stimulating hormone, thyroid hormone secretion, protein kinase A, protein kinase C, angiogenesis, paracrine signaling, thiouracil
MeSH terms
Calcimycin, Animals, Cell Division, Cells, Cultured, Bucladesine, Dose-Response Relationship, Drug, Graves Disease, Humans, Immunoglobulin G, Insulin, Kinetics, Lymphokines, Proto-Oncogene Proteins, RNA, Messenger, Tetradecanoylphorbol Acetate, Thiouracil, Thyroid Gland, Thyrotropin, DNA Probes, Gene Expression, Endothelial Growth Factors, Culture Media, Conditioned, Receptors, Growth Factor, Receptor Protein-Tyrosine Kinases, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review